BRPI0507473B8 - cápsula de gelatina mole, uso de epa, processo para a manufatura de uma cápsula de gelatina mole, e, uso de uma gelatina porcina tipo a em uma cápsula de gelatina mole - Google Patents

cápsula de gelatina mole, uso de epa, processo para a manufatura de uma cápsula de gelatina mole, e, uso de uma gelatina porcina tipo a em uma cápsula de gelatina mole

Info

Publication number
BRPI0507473B8
BRPI0507473B8 BRPI0507473A BRPI0507473A BRPI0507473B8 BR PI0507473 B8 BRPI0507473 B8 BR PI0507473B8 BR PI0507473 A BRPI0507473 A BR PI0507473A BR PI0507473 A BRPI0507473 A BR PI0507473A BR PI0507473 B8 BRPI0507473 B8 BR PI0507473B8
Authority
BR
Brazil
Prior art keywords
soft gelatin
gelatin capsule
capsule
soft
manufacturing
Prior art date
Application number
BRPI0507473A
Other languages
English (en)
Portuguese (pt)
Inventor
Sachetto Jean-Pierre
Bufton Roly
Buser Thomas
Original Assignee
Chrysalis Pharma Ag
Tillotts Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32011882&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0507473(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chrysalis Pharma Ag, Tillotts Pharma Ag filed Critical Chrysalis Pharma Ag
Publication of BRPI0507473A publication Critical patent/BRPI0507473A/pt
Publication of BRPI0507473B1 publication Critical patent/BRPI0507473B1/pt
Publication of BRPI0507473B8 publication Critical patent/BRPI0507473B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BRPI0507473A 2004-02-13 2005-02-07 cápsula de gelatina mole, uso de epa, processo para a manufatura de uma cápsula de gelatina mole, e, uso de uma gelatina porcina tipo a em uma cápsula de gelatina mole BRPI0507473B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0403247A GB0403247D0 (en) 2004-02-13 2004-02-13 A pharmaceutical composition
GB0403247.0 2004-02-13
PCT/GB2005/000415 WO2005079853A2 (fr) 2004-02-13 2005-02-07 Composition pharmaceutique

Publications (3)

Publication Number Publication Date
BRPI0507473A BRPI0507473A (pt) 2007-07-10
BRPI0507473B1 BRPI0507473B1 (pt) 2018-06-19
BRPI0507473B8 true BRPI0507473B8 (pt) 2021-05-25

Family

ID=32011882

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0507473A BRPI0507473B8 (pt) 2004-02-13 2005-02-07 cápsula de gelatina mole, uso de epa, processo para a manufatura de uma cápsula de gelatina mole, e, uso de uma gelatina porcina tipo a em uma cápsula de gelatina mole

Country Status (23)

Country Link
US (6) US7960370B2 (fr)
EP (1) EP1755565B2 (fr)
JP (3) JP5435842B2 (fr)
KR (1) KR101198458B1 (fr)
CN (1) CN1929824B (fr)
AR (1) AR047799A1 (fr)
AT (1) ATE457720T2 (fr)
AU (1) AU2005215198B2 (fr)
BR (1) BRPI0507473B8 (fr)
CA (1) CA2555064C (fr)
CY (1) CY1110030T1 (fr)
DE (1) DE602005019402D1 (fr)
DK (1) DK1755565T4 (fr)
ES (1) ES2344208T5 (fr)
GB (1) GB0403247D0 (fr)
IL (1) IL177462A (fr)
MX (1) MXPA06008352A (fr)
NO (1) NO341821B1 (fr)
PL (1) PL1755565T5 (fr)
PT (1) PT1755565E (fr)
SI (1) SI1755565T2 (fr)
WO (1) WO2005079853A2 (fr)
ZA (1) ZA200606229B (fr)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1660047T3 (pl) 2003-08-13 2014-05-30 Biocon Ltd Formulacje dawek stałych mikrocząsteczek soli kwasów tłuszczowych do środków terapeutycznych
GB0403247D0 (en) 2004-02-13 2004-03-17 Tillotts Pharma Ag A pharmaceutical composition
WO2009004999A1 (fr) * 2007-06-29 2009-01-08 Takeda Pharmaceutical Company Limited Capsule sans soudure
US9763989B2 (en) 2007-08-03 2017-09-19 Shaklee Corporation Nutritional supplement system
WO2009020595A2 (fr) * 2007-08-03 2009-02-12 Shaklee Corporation Système de complément nutritionnel
PL2334295T3 (pl) 2008-09-02 2017-12-29 Amarin Pharmaceuticals Ltd Kompozycja farmaceutyczna zawierająca kwas eikozapentaenowy i kwas nikotynowy oraz sposoby jej zastosowania
WO2010040012A1 (fr) * 2008-10-01 2010-04-08 Martek Biosciences Corporation Compositions et procédés de réduction de taux de triglycérides
US9314444B2 (en) 2009-01-12 2016-04-19 Biokier, Inc. Composition and method for treatment of NASH
US9006288B2 (en) 2009-01-12 2015-04-14 Biokier, Inc. Composition and method for treatment of diabetes
EP2405902B1 (fr) * 2009-03-09 2021-07-21 Basf As Compositions comprenant un mélange d'huile d'acide gras et d'agent tensio-actif, et leurs procédés et utilisations
US8207363B2 (en) 2009-03-19 2012-06-26 Martek Biosciences Corporation Thraustochytrids, fatty acid compositions, and methods of making and uses thereof
EP2424521A4 (fr) 2009-04-29 2015-03-04 Amarin Pharmaceuticals Ie Ltd Compositions pharmaceutiques comprenant de l'epa et un agent cardiovasculaire et leurs procédés d'utilisation
CN102458109B (zh) 2009-04-29 2015-02-11 阿马里纳制药公司 稳定的药物组合物和使用其的方法
KR102012111B1 (ko) 2009-06-15 2019-08-19 아마린 파마, 인크. 병용 스타틴 요법을 받는 대상체에서 ｌｄｌ－ｃ 수준을 상승시키지 않으면서 트리글리세리드를 저하시키기 위한 조성물 및 방법
SG10201405994UA (en) 2009-09-23 2014-10-30 Amarin Pharmaceuticals Ie Ltd Pharmaceutical Composition Comprising Omega-3 Fatty Acid And Hydroxy-derivative Of A Statin And Methods Of Using Same
KR20200013123A (ko) * 2009-10-23 2020-02-05 바스프 에이에스 지방산 오일 혼합물의 코팅된 캡슐 및 정제
JP2011136927A (ja) * 2009-12-28 2011-07-14 Pfizer Inc ゼラチンカプセル及びカプセル皮膜成形用ゼラチン組成物
CN102884201B (zh) 2010-01-19 2016-04-13 帝斯曼知识产权资产管理有限公司 生产二十碳五烯酸的微生物、脂肪酸组成物及其制作方法与用途
EP2613766A4 (fr) * 2010-09-08 2014-04-09 Pronova Biopharma Norge As Compositions comprenant un mélange d'huile constituée d'acides gras comprenant epa et dha sous forme d'acide libre, un tensioactif et une statine
US9415035B2 (en) 2010-09-17 2016-08-16 Maine Natural Health Company, Inc. Compositions containing omega-3 oil with an anti-inflammatory agent and uses thereof
WO2012037311A1 (fr) 2010-09-17 2012-03-22 Maine Natural Health, Inc. Compositions contenant de l'huile oméga-3 et leurs utilisations
NZ712068A (en) 2010-11-29 2017-03-31 Amarin Pharmaceuticals Ie Ltd Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US8951514B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Statin and omega 3 fatty acids for reduction of apolipoprotein-B levels
US8715648B2 (en) 2011-02-16 2014-05-06 Pivotal Therapeutics Inc. Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics
US8952000B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events
US9119826B2 (en) 2011-02-16 2015-09-01 Pivotal Therapeutics, Inc. Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels
CN108771240A (zh) 2011-07-21 2018-11-09 帝斯曼知识产权资产管理有限公司 脂肪酸组合物
WO2013040507A1 (fr) * 2011-09-15 2013-03-21 Omthera Pharmaceuticals, Inc. Méthodes et compositions pour traiter, inverser, inhiber ou prévenir la résistance à la thérapie antiplaquettaire
EP2775837A4 (fr) 2011-11-07 2015-10-28 Amarin Pharmaceuticals Ie Ltd Méthodes de traitement de l'hypertriglycéridémie
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
PL2800563T3 (pl) * 2012-01-06 2018-12-31 Omthera Pharmaceuticals Inc. Wzbogacone w DPA kompozycje wielonienasyconych kwasów tłuszczowych omega-3 w postaci wolnego kwasu
WO2013103958A1 (fr) 2012-01-06 2013-07-11 Amarin Pharmaceuticals Ireland Limited Compositions et procédés pour abaisser les taux de crp à haute sensibilité (hs-crp) chez un sujet
EP2833740B1 (fr) * 2012-04-04 2016-09-14 Pronova BioPharma Norge AS Compositions comprenant des acides gras oméga-3 et de la vitamine d destinées à lutter contre l'acné vulgaire et/ou l'eczéma, et méthodes et utilisations associées
US20130280323A1 (en) * 2012-04-13 2013-10-24 Banner Pharmacaps, Inc. Soft Elastic Capsules Containing Tablets and Liquid or Semisolid Fills and Methods for Their Manufacture
NO2659881T3 (fr) 2012-04-30 2018-04-28
JP6173437B2 (ja) * 2012-05-07 2017-08-02 オムセラ・ファーマシューティカルズ・インコーポレイテッド スタチン及びω−３脂肪酸の組成物
SG11201408769QA (en) 2012-06-29 2015-01-29 Amarin Pharmaceuticals Ie Ltd Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
GB201216385D0 (en) * 2012-09-13 2012-10-31 Chrysalis Pharma Ag A pharmaceutical composition
US20150265566A1 (en) 2012-11-06 2015-09-24 Amarin Pharmaceuticals Ireland Limited Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
AU2013404367B2 (en) 2013-10-29 2020-02-27 Tillotts Pharma Ag A delayed release drug formulation
MX2016004487A (es) * 2013-10-30 2016-11-10 Banner Life Sciences Llc Capsulas blandas de capa entérica que constan de ácidos grasos poli insaturados.
US9326965B2 (en) 2014-02-28 2016-05-03 Banner Life Sciences Llc Controlled release fumarate esters
US9636318B2 (en) 2015-08-31 2017-05-02 Banner Life Sciences Llc Fumarate ester dosage forms
US9326947B1 (en) 2014-02-28 2016-05-03 Banner Life Sciences Llc Controlled release fumarate esters
US10098863B2 (en) 2014-02-28 2018-10-16 Banner Life Sciences Llc Fumarate esters
EP3140316A1 (fr) 2014-05-05 2017-03-15 Thetis Pharmaceuticals LLC Compositions et procédés se rapportant à des sels ioniques de peptides
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
US10172818B2 (en) 2014-06-16 2019-01-08 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
CN107074884A (zh) 2014-06-18 2017-08-18 西蒂斯制药有限责任公司 活性剂的矿物质氨基酸复合物
US9242008B2 (en) 2014-06-18 2016-01-26 Thetis Pharmaceuticals Llc Mineral amino-acid complexes of fatty acids
WO2015200563A1 (fr) * 2014-06-26 2015-12-30 Banner Life Sciences Llc Biodisponibilité améliorée d'acides gras polyinsaturés
US9895333B2 (en) 2014-06-26 2018-02-20 Patheon Softgels Inc. Enhanced bioavailability of polyunsaturated fatty acids
EP4218765A3 (fr) * 2014-08-28 2023-08-09 NewAmsterdam Pharma B.V. Composition pharmaceutique et combinaison thérapeutique comprenant un inhibiteur de la protéine de transfert de l'ester de cholestéryle et des inhibiteurs de la hmg coa réductase
CN105434393B (zh) * 2014-09-25 2019-07-09 四川国为制药有限公司 一种包含高含量ω-3多不饱和脂肪酸的软胶囊药物组合物
MA41611A (fr) 2015-02-23 2018-01-02 Omthera Pharmaceuticals Inc Préparations en milli-capsules comprenant des acides gras polyinsaturés libres
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
DK3454907T3 (da) 2016-06-03 2020-10-19 Thetis Pharmaceuticals Llc Sammensætninger og fremgangsmåder relateret til salte af specialiserede pro-løsningsmediatorer af inflammation
TW201900160A (zh) 2017-05-19 2019-01-01 愛爾蘭商艾瑪琳製藥愛爾蘭有限公司 用於降低腎功能下降之個體中的三酸甘油酯之組合物及方法
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
GB2571749A (en) * 2018-03-07 2019-09-11 Anabio Tech Limited A method inducing satiety in a mammal
KR102296068B1 (ko) 2018-09-24 2021-09-02 애머린 파마슈티칼스 아일랜드 리미티드 대상체에서 심혈관 사건의 위험도를 감소시키는 방법
CN109567180B (zh) * 2019-02-02 2022-03-22 北京振东光明药物研究院有限公司 一种可用于女性经、孕、产、乳期的营养品及其制备方法
US11903918B2 (en) 2020-01-10 2024-02-20 Banner Life Sciences Llc Fumarate ester dosage forms with enhanced gastrointestinal tolerability
CN113559079B (zh) * 2020-04-28 2023-10-20 江苏恒瑞医药股份有限公司 一种软胶囊及其制备方法和用途
KR20240012390A (ko) 2021-04-21 2024-01-29 애머린 파마슈티칼스 아일랜드 리미티드 심부전의 위험을 감소시키는 방법

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2868661A (en) * 1954-08-04 1959-01-13 Wilson & Co Inc Sensitizing photographic gelatin
US2870062A (en) 1956-04-27 1959-01-20 Scherer Corp R P Gelatin composition for capsules
US2888661A (en) 1956-12-13 1959-05-26 Radio Frequency Lab Adapter for magnet charger
US3108995A (en) 1957-03-01 1963-10-29 Charles B Knox Gelatine Co Inc Method of modifying type a gelatin and product thereof
AU527784B2 (en) 1978-05-26 1983-03-24 Bang, Hans Olaf Dr. Treatment of thromboembolic conditions withall-z)-5, 8, 11, 14, 17-eicosapentaenoic acid
JPS55154533A (en) 1979-05-18 1980-12-02 Kawasaki Steel Corp Stacking method for starting material such as ore
JPS5735512A (en) 1980-06-27 1982-02-26 Nippon Oil & Fats Co Ltd Preventive and remedy for thrombosis
JPS609011B2 (ja) 1981-10-09 1985-03-07 富士カプセル株式会社 軟カプセル皮膜
ZA835226B (en) 1982-07-19 1985-03-27 Syntex Inc Pge-type compositions encapsulated by acid isolated gelatin
JPS5939834A (ja) * 1982-08-31 1984-03-05 Morishita Jintan Kk 製剤用皮膜組成物
DE3438291A1 (de) 1984-10-19 1986-04-24 Röhm GmbH, 6100 Darmstadt Verfahren zur herstellung einer waessrigen ueberzugsmitteldispersion und ihre verwendung zum ueberziehen von arzneimitteln
EP0212746B1 (fr) 1985-08-16 1991-04-10 The Procter & Gamble Company Particules pour une libération constante de la substance active
SE8505569D0 (sv) 1985-11-25 1985-11-25 Aco Laekemedel Ab Enteralt preparat
IL77186A0 (en) 1985-11-29 1986-04-29 Touitou Elka Pharmaceutical insulin composition
JPS62201823A (ja) 1986-02-28 1987-09-05 Freunt Ind Co Ltd 腸内有用細菌含有物およびその製造方法
DE3615710A1 (de) 1986-05-09 1987-11-26 Hoechst Ag Zubereitungen fuer die synthese von prostaglandinen und hydroxyfettsaeuren in biologischen systemen
GB8707421D0 (en) 1987-03-27 1987-04-29 Wellcome Found Pharmaceutical formulations
EP0289204B1 (fr) 1987-04-27 1991-07-17 Efamol Holdings Plc Compositions pharmaceutiques contenant des sels de lithium
GB8719988D0 (en) 1987-08-25 1987-09-30 Efamol Ltd Chemical compounds
US5252333A (en) 1987-04-27 1993-10-12 Scotia Holdings Plc Lithium salt-containing pharmaceutical compositions
JPH0774150B2 (ja) * 1987-07-31 1995-08-09 新田ゼラチン株式会社 肝油用ソフトカプセル
US4895725A (en) 1987-08-24 1990-01-23 Clinical Technologies Associates, Inc. Microencapsulation of fish oil
DE3734147C2 (de) 1987-10-09 1998-10-29 Braun Melsungen Ag Isotone omega-3-fettsäurenhaltige Fettemulsion und ihre Verwendung
GB8819110D0 (en) * 1988-08-11 1988-09-14 Norsk Hydro As Antihypertensive drug & method for production
GB2223943A (en) * 1988-10-21 1990-04-25 Tillotts Pharma Ag Oral disage forms of omega-3 polyunsaturated acids
US4935243A (en) * 1988-12-19 1990-06-19 Pharmacaps, Inc. Chewable, edible soft gelatin capsule
PT93637A (pt) 1989-04-20 1990-11-20 Procter & Gamble Metodo para o tratamento de desordens funcionais intestinais/colonicas, especialmente o sindrome de irritacao intestinal
US5292522A (en) 1989-06-20 1994-03-08 Rohm Gmbh Aqueous film coating agent for solid medicaments
JP2836206B2 (ja) 1990-07-02 1998-12-14 味の素株式会社 炎症性腸疾患用油脂組成物
KR100193933B1 (ko) 1990-07-20 1999-06-15 에밀리오 캠포레시, 존 페르구손 비스무트와 폴리아크릴레이트와의 수용성 착체, 이의 제조 방법 및 상기 착체 또는 다른 비스무트염을 함유하는 궤양성 대장염 치료용 약제학적 조성물
GB2253346A (en) 1991-02-22 1992-09-09 John Rhodes Delayed release oral dosage forms for treatment of intestinal disorders
EP0637957B1 (fr) 1992-04-28 1997-07-23 Fresenius AG Utilisation d'une emulsion contenant des acides gras omega-3 pour la fabrication d'un medicament administrable par voie parenterale, pour le traitement de maladies inflammatoires
US5496718A (en) 1992-06-26 1996-03-05 Seikagaku Kogyo Kabushiki Kaisha (Seikagaku Corporation) Chondroitinase ABC isolated from proteus vulgaris ATCC 6896
JP3895782B2 (ja) 1992-10-26 2007-03-22 生化学工業株式会社 コンドロイチナーゼ組成物およびそれを含有する注射用製剤
EP0670717B1 (fr) 1992-11-30 1998-11-25 Pfizer Inc. Dispositif de distribution a membrane de retenue de liquide
JPH0741421A (ja) 1993-05-28 1995-02-10 Suntory Ltd ロイコトリエンｂ４ （ｌｔｂ４ ）による医学的症状の予防及び改善剤
DK66493D0 (da) 1993-06-08 1993-06-08 Ferring A S Praeparater, isaer til brug ved behandling af inflammatoriske tarmsygdomme eller til at opnaa forbedret saarheling
DE4422938A1 (de) 1993-06-30 1995-01-12 Siegfried Ag Pharma Neue Weichgelatinekapseln
US5411988A (en) 1993-10-27 1995-05-02 Bockow; Barry I. Compositions and methods for inhibiting inflammation and adhesion formation
US5641512A (en) * 1995-03-29 1997-06-24 The Procter & Gamble Company Soft gelatin capsule compositions
GB9509764D0 (en) 1995-05-15 1995-07-05 Tillotts Pharma Ag Treatment of inflammatory bowel disease using oral dosage forms of omega-3 polyunsaturated acids
JPH11106333A (ja) * 1997-09-30 1999-04-20 Kuraray Co Ltd 脂溶性ビタミンおよび／またはカロチノイドを含有する粉末の製造法
DE19830375A1 (de) 1998-07-08 2000-01-13 K D Pharma Bexbach Gmbh Mikroverkapselte ungesättigte Fettsäure oder Fettsäureverbindung oder Mischung aus Fettsäuren und/oder Fettsäureverbindungen
JP2003510348A (ja) 1999-10-01 2003-03-18 ナトコ ファーマ リミテッド 改良された薬学的組成物およびその製造方法
US6555316B1 (en) * 1999-10-12 2003-04-29 Genset S.A. Schizophrenia associated gene, proteins and biallelic markers
KR20020059719A (ko) * 1999-11-12 2002-07-13 추후보정 재조합 젤라틴
JP2001335481A (ja) 2000-03-22 2001-12-04 Eisai Co Ltd 高濃度ビタミンｅ含有ソフトカプセル
ITMI20012384A1 (it) 2001-11-12 2003-05-12 Quatex Nv Uso di acidi grassi poliinsaturi per la prevenzione primaria di eventi cardiovascolari maggiori
US20030161872A1 (en) * 2002-01-04 2003-08-28 Gan-Lin Chen Capsule for holding liquid-containing compositions and method for making the same
US6663900B2 (en) * 2002-02-01 2003-12-16 Kemin Foods, Lc Microcapsules having high carotenoid content
ITMI20020269A1 (it) 2002-02-12 2003-08-12 Victorix Assets Ltd Uso di steri etilici di acidi poliinsaturi omega-3 in pazienti con insufficienza cardiaca
DE10214002A1 (de) 2002-03-27 2003-10-09 Roehm Gmbh Pharmazeutische Formulierung für den Wirkstoff Budesonid
ITMI20020731A1 (it) 2002-04-08 2003-10-08 Ibsa Inst Biochimique Sa Composizioni farmaceutiche per acido acetilsalicilico e oli omega-3
US6974592B2 (en) * 2002-04-11 2005-12-13 Ocean Nutrition Canada Limited Encapsulated agglomeration of microcapsules and method for the preparation thereof
GB2388776B (en) 2002-05-21 2004-08-25 Croda Int Plc Succinylated fish gelatin for use as a blood plasma expander
AU2003240536B2 (en) 2002-06-05 2007-11-15 Ivax Pharmaceuticals, S.R.O. Reduction of gelatin cross-linking
EP1617734A1 (fr) * 2003-04-17 2006-01-25 Boehringer Ingelheim International GmbH Complement multivitamine et mineral pour femmes enceintes
GB0403247D0 (en) * 2004-02-13 2004-03-17 Tillotts Pharma Ag A pharmaceutical composition
GB0413729D0 (en) 2004-06-18 2004-07-21 Tillotts Pharma Ag A pharmaceutical composition and its use

Also Published As

Publication number Publication date
CA2555064A1 (fr) 2005-09-01
DE602005019402D1 (de) 2010-04-01
IL177462A0 (en) 2006-12-10
US20140228437A1 (en) 2014-08-14
US20070269507A1 (en) 2007-11-22
JP5435842B2 (ja) 2014-03-05
AU2005215198B2 (en) 2010-01-14
BRPI0507473A (pt) 2007-07-10
ES2344208T3 (es) 2010-08-20
PT1755565E (pt) 2010-04-26
SI1755565T1 (sl) 2010-08-31
CN1929824A (zh) 2007-03-14
US8383678B2 (en) 2013-02-26
EP1755565B2 (fr) 2018-02-07
DK1755565T3 (da) 2010-05-03
US9012501B2 (en) 2015-04-21
JP2007522192A (ja) 2007-08-09
US20150238430A1 (en) 2015-08-27
PL1755565T3 (pl) 2010-09-30
CA2555064C (fr) 2011-07-05
PL1755565T5 (pl) 2018-06-29
JP2012149073A (ja) 2012-08-09
BRPI0507473B1 (pt) 2018-06-19
US7960370B2 (en) 2011-06-14
WO2005079853A3 (fr) 2006-01-12
ES2344208T5 (es) 2018-05-17
DK1755565T4 (en) 2018-05-22
MXPA06008352A (es) 2007-05-23
KR101198458B1 (ko) 2012-11-06
NO341821B1 (no) 2018-01-29
CY1110030T1 (el) 2015-01-14
CN1929824B (zh) 2011-03-23
JP2014139216A (ja) 2014-07-31
US20110097394A1 (en) 2011-04-28
AU2005215198A1 (en) 2005-09-01
ZA200606229B (en) 2009-12-30
SI1755565T2 (en) 2018-04-30
US20130123362A1 (en) 2013-05-16
GB0403247D0 (en) 2004-03-17
AR047799A1 (es) 2006-02-22
IL177462A (en) 2015-09-24
ATE457720T2 (de) 2010-03-15
EP1755565A2 (fr) 2007-02-28
KR20070011307A (ko) 2007-01-24
US9132112B2 (en) 2015-09-15
WO2005079853A2 (fr) 2005-09-01
EP1755565B1 (fr) 2010-02-17
US20170056354A1 (en) 2017-03-02
NO20064146L (no) 2006-11-10

Similar Documents

Publication Publication Date Title
BRPI0507473B8 (pt) cápsula de gelatina mole, uso de epa, processo para a manufatura de uma cápsula de gelatina mole, e, uso de uma gelatina porcina tipo a em uma cápsula de gelatina mole
ES2524320T3 (es) Composición para la prevención o el tratamiento de enfermedad asociada con trombo o émbolo
AR050717A1 (es) Composiciones farmaceuticas
BRPI0412059A (pt) método para a preparação de formulação de liberação controlada
CO4900058A1 (es) Terapia de combinacion para el tratamiento de psicosis
BRPI0607569A2 (pt) composição farmacêutica compreendendo estatina e ácidos graxos Èmega-3, na forma de dosagem unitária
BR0210267A (pt) Composição farmacêutica sólida, processo para preparar a mesma, conjunto para o tratamento de obesidade, utilização da composição, processo de tratamento de obesidade e inibidor de lìpases
PE20070618A1 (es) Composicion farmaceutica que contiene rosiglitazona en el tratamiento de alzheimer
BRPI0819231B8 (pt) processo para preparo de forma farmacêutica de desintegração rápida por moldagem a quente na presença de sal inorgânico hidratado
AR078952A1 (es) Formulaciones de comprimidos revestidos
ECSP077999A (es) Formulaciones de una sal de bupropion de liberación modificada
BRPI0508758B8 (pt) composição de cloridrato de oxicodona apresentatando menos do que100 ppm de 14 - hidroxicodeinona, e seus processos de preparação
SV2008002527A (es) Composicion farmaceutica que contiene gestagenos y/o estrogenos y 5-metil-(6s)-tetrahidrofolato ref. p-sv-80.273/ug
AR012671A1 (es) Composiciones farmaceuticas para el tratamiento o profilaxis de la constipacion, los usos de dichas composiciones y los procesos para prepararlos
CO2018005842A2 (es) Composición farmacéutica que comprende un potente inhibidor de urat 1
BRPI0802405A2 (pt) agente de liberação de molde livre de solvente e sua aplicação na preparação de artigos moldados de poliuretano
AR094374A1 (es) Composiciones y métodos para el tratamiento de trastornos metabólicos
BRPI0603304A (pt) método para a restauração de uma parte de um componente de uma turbina
BRPI0511355A (pt) composição para aplicação tópica na pele de mamìferos, seu uso, métodos para confecção de composições, método para o tratamento da psorìase e método para o tratamento do eczema
BRPI0411952A (pt) método para a fabricação de um artigo moldado tendo uma marca especìfica sobre a superfìcie do mesmo e artigo moldado
CO6321129A2 (es) Inhibidor de la cristalizacion y su uso en capsulas de gelatina
CO2024000054A2 (es) Forma cristalina de tolebrutinib y método de preparación y su uso
BRPI0606528A8 (pt) composição para uso no fabrico de medicamentos de tratamento da infertilidade masculina e uso da mesma
BRPI0412697A (pt) composições farmacêuticas que apresentam um revestimento expansìvel
BR122021012549B8 (pt) Composição de dissolução oral de melatonina com agente acidificante que torna melatonina solúvel em saliva

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25G Requested change of headquarter approved

Owner name: TILLOTTS PHARMA AG (CH)

B25A Requested transfer of rights approved

Owner name: CHRYSALIS PHARMA AG (CH)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 07/02/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 17A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2656 DE 30-11-2021 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.